FDA Noxafil Approval Delayed By Last-Minute Label, Data Integrity Issues
FDA overshot the user fee goal on Schering-Plough's Noxafil (posaconazole) to address labeling and data integrity issues that arose late in the review of the antifungal, FDA review documents indicate
You may also be interested in...
Schering-Plough's Noxafil (posaconazole) is the first antifungal approved by FDA for the prevention of invasive fungal infections caused by Aspergillus species
An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings
US FDA Revisits Gonorrhea Drug Development As Fast-Emerging Resistance, Preclinical Challenges Hold Back New Products
From animal models to non-inferiority margins, US FDA is seeking new perspectives on gonorrhea R&D, including how to incorporate extragenital infections into clinical programs.